XML 64 R46.htm IDEA: XBRL DOCUMENT
v3.25.0.1

FAIR VALUE MEASUREMENTS (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Fair Value Disclosures [Abstract] |
Schedule of Fair Value Measurements, Recurring and Nonrecurring | Assets and liabilities measured and recorded at fair value on a recurring basis as of December 31, 2024, 2023, and 2022 consisted of the following:
|  | Years Ended
Dollars in thousands | Fair Value Measurement | 2024 | 2023 | 2022
Assets: |  |  |  |
Cash and cash equivalents | Level 1 | $ | 246,375 |  | $ | 276,402 |  | $ | 456,661 |
Short-term investments | Level 1 | 27,192 |  | 32,694 |  | — |
Interest rate swaps | Level 2 | 48,795 |  | 43,556 |  | 56,712 |
Pension plan assets | Level 2 | 51,818 |  | 45,724 |  | 38,053 |
Foreign currency forward contracts (not designated as hedges) | Level 2 | 1,700 |  | 1,200 |  | 1,100 |
Total Assets: |  | $ | 375,880 |  | $ | 399,576 |  | $ | 552,526 |
Liabilities: |  |  |  |
Cross currency rate swaps | Level 2 | $ | 4,367 |  | $ | 40,672 |  | $ | 7,769 |
Net investment hedges | Level 2 | 31,113 |  | 49,609 |  | 5,643 |
Foreign currency forward contracts | Level 2 | 914 |  | — |  | — |
Contingent consideration | Level 3 | 69,657 |  | 87,312 |  | 74,432 |
Pension project benefit obligation | Level 2 | 67,262 |  | 65,101 |  | 50,364 |
Total Liabilities: |  | $ | 173,313 |  | $ | 242,694 |  | $ | 138,208 |
Schedule of Contingent Consideration | A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the years ended December 31, 2024 and 2023 is as follows (in thousands):
|  | Contingent Consideration Liability Related to Acquisition of: |  |
| Arkis |  | Location in Financial Statements |  | Derma Sciences |  | ACell |  | Surgical Innovations Associates, Inc. |  | Location in Financial Statements
Balance as of January 1, 2024 |  | $ | 15,755 |  |  |  |  | $ | 2,557 |  |  | $ | 300 |  |  |  |  | $ | 68,700 |  |  |
Payments |  | — |  |  |  |  | — |  |  | — |  |  |  |  | (12,400) |  |  |
Change in fair value of contingent consideration liabilities |  | (2,787) |  |  | Research and development |  | 129 |  |  | (297) |  |  |  |  | (2,300) |  |  | Selling, general and administrative
Balance as of December 31, 2024 |  | $ | 12,968 |  |  |  |  | $ | 2,686 |  |  | $ | 3 |  |  |  |  | $ | 54,000 |  |  |
Short-Term |  | $ | 8,560 |  |  |  |  | $ | — |  |  | $ | — |  |  |  |  | $ | 17,900 |  |  | Accrued expenses and other current liabilities
Long-Term |  | 4,408 |  |  |  |  | 2,686 |  |  | 3 |  |  |  |  | 36,100 |  |  | Other liabilities
Total |  | $ | 12,968 |  |  |  |  | $ | 2,686 |  |  | $ | 3 |  |  |  |  | $ | 54,000 |  |  |
|  | Contingent Consideration Liability Related to Acquisition of: |  |
| Arkis |  | Location in Financial Statements |  | Derma Sciences |  |  |  | ACell Inc. |  | Surgical Innovations Associates, Inc. |  | Location in Financial Statements
Balance as of January 1, 2023 |  | $ | 12,895 |  |  |  |  | $ | 230 |  |  |  |  | $ | 3,700 |  |  | $ | 57,607 |  |  |
Additions |  | — |  |  |  |  | — |  |  |  |  | — |  |  | — |  |  |
Change in fair value of contingent consideration liabilities |  | 2,860 |  |  | Research and development |  | 2,327 |  |  |  |  | (3,400) |  |  | 11,093 |  |  | Selling, general and administrative
Balance as of December 31, 2023 |  | $ | 15,755 |  |  |  |  | $ | 2,557 |  |  |  |  | $ | 300 |  |  | $ | 68,700 |  |  |
Short-Term |  | $ | 7,778 |  |  |  |  | $ | — |  |  |  |  | $ | — |  |  | $ | 13,400 |  |  | Accrued expenses and other current liabilities
Long-Term |  | 7,977 |  |  |  |  | 2,557 |  |  |  |  | 300 |  |  | 55,300 |  |  | Other liabilities
Total |  | $ | 15,755 |  |  |  |  | $ | 2,557 |  |  |  |  | $ | 300 |  |  | $ | 68,700 |  |  |
A rollforward of the fair value of the contingent consideration liabilities, as determined by Level 3 unobservable inputs, during the years ended December 31, 2024, December 31, 2023, and December 31, 2022 were as follows:
| Years Ended
Dollars in thousands | 2024 | 2023 | 2022
Balance at beginning of period | $ | 87,312 |  | $ | 74,432 |  | $ | 37,129 |
Change in fair value | (5,255) |  | 12,880 |  | 37,303 |
Payments | (12,400) |  | — |  | — |
Balance at end of period | $ | 69,657 |  | $ | 87,312 |  | $ | 74,432 |

X
- Definition Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration